Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications

• Published in: Annals of Pharmacotherapy 2015-04, Vol.49 (4), p.437-447
• Main Authors: Nyandege, Abner N., Slattum, Patricia W., Harpe, Spencer E.
• Format: Article
• Language: English
• Subjects: Bone Density Conservation Agents - therapeutic use; Diphosphonates - therapeutic use; Female; Fractures, Bone - epidemiology; Fractures, Bone - etiology; Fractures, Bone - prevention & control; Humans; Osteoporosis - chemically induced; Osteoporosis - complications; Osteoporosis - drug therapy; Risk
• ISSN: 1060-0280; 1542-6270
• DOI: 10.1177/1060028015569594

Objective: To review the literature on the concomitant use of bisphosphonates and medications that can influence bone metabolism and potentially attenuate bisphosphonate antifracture efficacy. Data Sources: MEDLINE and CINAHL were searched for articles published in English through December 2014 using the following terms: bisphosphonates, bone density conservation agents, acid-suppressive therapy, levothyroxine, thiazolidinediones (TZDs), selective serotonin reuptake inhibitors (SSRIs), bone fractures. Study Selection and Data Extraction: Studies were included if they reported results of concomitant use of any listed medications with bisphosphonates and risk of fractures and focused on women. Articles that focused generally on the use of one of the listed medications and fractures without explicitly examining the potential antifracture efficacy or attenuation of bisphosphonates were excluded. Data Synthesis: A total of 6 relevant studies were identified. Four epidemiological studies reported a statistically significant dose-dependent increase in the risk of fractures when bisphosphonates and acid-suppressive drugs were used together. One post hoc analysis of clinical trial data suggested no attenuation of the antifracture effects of bisphosphonates when used concomitantly with acid-suppressive therapy. One study involving bisphosphonates and SSRIs noted a statistically significant association between fracture risk and SSRI use. No study examining TZDs or levothyroxine with bisphosphonates was identified. Conclusions: Existing research suggests potential attenuation of bisphosphonate antifracture efficacy among patients taking acid-suppressive medications. Based on their pharmacological actions, TZDs, SSRIs, and levothyroxine have similar implications. The paucity of evidence in the literature associating the attenuation of bisphosphonate antifracture efficacy when combined with other medications suggests that further investigation is needed.